Identification

Brand Name
Herceptin
Product Description
Herceptin is a prescription HER2 receptor antagonist available in multiple countries including the United States, Canada, the EU, Italy, and Indonesia. It was first marketed in 1998. It is available in an Intravenous Injection and a Subcutaneous Injection. It contains one active ingredient: Trastuzumab. Trastuzumab is an injectable medication used to treat certain types of cancers that overexpress the HER2 protein.
Ingredients
DrugSalt
TrastuzumabNot Available

Pharmacology

Indications
Treatment of Breast Cancer Prescription
Treatment of Metastatic Breast Cancer Prescription
Treatment of Metastatic Gastric Adenocarcinoma Prescription
Treatment of Metastatic Gastroesophageal Junction Adenocarcinoma Prescription
Used in combination for prophylaxis of Rejection Acute Renal in a regimen Prescription
Used in combination to manage Rejection Acute Renal in a regimen Prescription
Used in combination to treat Acute Lymphoblastic Leukemia (ALL) in a regimen Prescription
Used in combination to treat Breast Cancer in a regimen Prescription
Used in combination to treat Early Breast Cancer in a regimen Prescription
Used in combination to treat Inflammatory Breast Cancer (IBC) in a regimen Prescription
Used in combination to treat Locally Advanced Breast Cancer (LABC) in a regimen Prescription
Used in combination to treat Lymphoma, Lymphoblastic in a regimen Prescription
Used in combination to treat Metastatic Adenocarcinoma of the Gastroesophageal Junction in a regimen Prescription
Used in combination to treat Metastatic Adenocarcinoma of the Stomach in a regimen Prescription
Used in combination to treat Metastatic Breast Cancer in a regimen Prescription
Used in combination to treat Unresectable Breast Cancer in a regimen Prescription
Products
DosageStrengthRouteLabellerMarketing StartMarketing EndNDC Code
Injection, solution600 mgSubcutaneousRoche Registration Gmb H2016-09-08-EU flag EU/1/00/145/003
Injection, powder, for solution150 mgIntravenousRoche Registration Gmb H2016-09-08-EU flag EU/1/00/145/001
Powder, for solution440 mg / vialIntravenousHoffmann La Roche1999-08-23-Canada flag 02240692
Injection, solution600 mgSubcutaneousRoche Registration Gmb H2016-09-08-EU flag EU/1/00/145/002
Injection, powder, for solution150 MGIntravenousRoche Registration Gmbh2014-07-08-Italy flag 034949014
Injection, solution600 MG/5MLParenteral; SubcutaneousRoche Registration Gmbh2014-07-08-Italy flag 034949026
Injection, solution600 MGParenteral; SubcutaneousRoche Registration Gmbh2015-05-23-Italy flag 034949038
Injection600 MG/5MLParenteralBoehringer Ingelheim Indonesia2018-05-232023-05-23Indonesia flag DKI1857507343A1
Injection, powder, for solutionIntravenousBoehringer Ingelheim Indonesia2017-11-212022-11-21Indonesia flag DKI1657507044B1
Injection, powder, for solutionBoehringer Ingelheim Indonesia2016-10-312025-10-19Indonesia flag DKI1454500144A1
Injection150 mg/7.4mLIntravenousGenentech, Inc.1998-09-25-US flag 50242-134
Injection, powder, lyophilized, for solution150 mg/7.4mLIntravenousGenentech, Inc.2017-02-10-US flag 50242-132
420 mg/20mLIntravenousGenentech, Inc.1998-09-25-US flag 50242-333

Interactions